Whooping Cough Vaccination

*One dose of Boostrix is funded for those 65 years and over, and for those 45 years and over who have not had 4 previous tetanus doses.

References:

1. Ministry of Health. Immunisation Handbook 2020. September 2020. Wellington. Ministry of Health. Available at: https://www.health.govt.nz/publication/immunisation-handbook-2020. Accessed on 2 June 2020.
2. Kandeil W et al. Expert Review of Vaccines.2019;18:439-455.
3. Pertussis. Questions and Answers. Available at: http://www.immunize.org/catg.d/p4212.pdf. Accessed on 2 June 2021.
4. Pertussis. Causes and Transmission. Available at: https://www.cdc.gov/pertussis/about/causes-transmission.html. Accessed on 2 June 2021.
5. Fine PE, et al. Epidemiologic reviews1993;15:265-302.
6. The Immunisation Advisory Centre. Pertussis. Available at: https://www.immune.org.nz/diseases/pertussis. Accessed on 2 June 2021.
7. Marchant, C. Clinical Infectious Diseases.2004;39:1581–1582
8. Mattoo S, and Cherry JD. Clinical Microbiology Reviews.2005;18:326-382.
9. Simon AK, et al. Proceedings Biological Sciences.2015;282:1-9
10. Philip R.K., et al. Expert Review of Vaccines.2018;17:851-864.
11. Steens A, et al. BMC Infectious Diseases.2014;14:1471-2334.
12. Liu BC, et al. Clinical Infectious Diseases.2012;55:1450-1456
13. Karki S, et al. Vaccine.2015;33:5647–5653
14. ACOG Committee Opinion. Number 718, September 2017. Available at: https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Immunization-Infectious-Disease-and-Public-Health-Preparedness-Expert-Work-Group/Maternal-Immunization. Accessed 18 June 2021.
15. Wendelboe AM, et al. Pediatric Diseases. 2007;26:293-299.
16. GlaxoSmithKline New Zealand. Boostrix Data Sheet. GSK NZ; 2020. Available at: https://www.medsafe.govt.nz/Profs/Datasheet/b/Boostrixinj.pdf. Accessed 2 June 2021.
17. GSK Data on File. IQVIA Whooping Cough Consumer Survey. September 2018.

Boostrix (combined diphtheria, tetanus, and acellular pertussis (dTpa or Tdap) vaccine) is available as an injection. Boostrix is indicated for booster immunisation of people aged 4 years and older against diphtheria, tetanus, and pertussis (whooping cough). A 0.5 mL dose contains not less than 2.5 LfU of diphtheria toxoid, not less than 5 LfU of tetanus toxoid, and three purified antigens of Bordetella pertussis (8mcg of pertussis toxoid, 8 mcg of filamentous haemagglutinin, and 2.5 mcg of 69 kDa outer membrane protein). Boostrix is government funded for 11-year olds as part of the national immunisation schedule, for pregnant women between 16 and 38 weeks gestation (Category B1) and for primary caregivers of infants admitted to Intensive Care Units for more than 3 days. It is also funded for people from 65 years old, and people from 45 years old who have not had 4 previous doses of tetanus vaccine, for vaccination of previously unimmunised or partially immunised patients, for revaccination following immunosuppression and for boosting of patients with tetanus-prone wounds. It is also available as a private-purchase prescription medicine – you will need to pay for this medicine, normal doctor’s office visit fees apply. A trained pharmacist can also administer Boostrix to a person aged 18 years and older. Tell your healthcare professional if you are pregnant or breastfeeding to be informed of the benefits and risks of Boostrix. Boostrix has risks and benefits. Use strictly as directed. Boostrix should not be administered if you or your child are hypersensitive to any component of this vaccine or similar vaccines or have had swelling or disease of the brain after previous pertussis (whooping cough) vaccination, or any problems with blood clotting or the nervous system (such as spasms, epilepsy and brain disease) after earlier immunisation against diphtheria or tetanus. Common side effects include fever, irritability, fatigue, malaise, headache, loss of appetite, vomiting and diarrhoea, and local reactions such as pain, redness, bruising, itching, or swelling at the injection site. If you have side effects, see your doctor, pharmacist, or healthcare professional. Additional Consumer Medicine Information for Boostrix is available at www.medsafe.govt.nz. Ask your doctor if Boostrix is right for you or your child. Trade marks are owned by or licensed to the GSK group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP18486-PM-NZ-BOO-WCNT-210003. Date of Approval: 10 2022. Date of Expiry: 10 2024.